Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3983-3988

  Nakayama, Yoshifumi ^a   Matsumoto, Kentaro ^a   Inoue, Yuzuru ^a   Katsuki, Takefumi ^a   Kadowaki, Koji ^a   Shibao, Kazunori ^a   Tsurudome, Yosuke ^a   Hirata, Keiji ^a   Sako, Tatsuhiko ^a   Nagata, Naoki ^a   Itoh, Hideaki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

5 FU; Cancer; Dihydrouracil uracil; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; DIHYDROURACIL; DOXIFLURIDINE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; OXONIC ACID; TEGAFUR; URACIL;

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG BLOOD LEVEL; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; STOMACH CANCER; URINALYSIS;

ADMINISTRATION, ORAL; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROURACIL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; URACIL;

EID: 33750713063     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y and Taguchi T: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivate for advanced and recurrent gastrointestinal cancers, The S-1 Gastrointestinal Cancer Study Group. Oncology 57: 202-210, 1999.
2. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T and Shirasaka T: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5: 2000-2005, 1999.
3. Fleming GF, Schilsky RL, Schumm LP, Meyerson A, Hong M, Vogelzang NJ and Ratain MJ: Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leukovorin in patients with organ dysfunction. Annals of Oncology 14: 1142-1147, 2003.
4. Joulia JM, Pinguet F, Ychou M, Duffour J, Topart D, Grosse PY, Astre C and Bressolle F: Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folic acid (LV5FU2). Anticancer Res 17: 2727-2730, 1997.
5. Perignon JL, Bories DM and Houllier AM: Metabolism of pyrimidine based and nucleosides by pyrimidine-nucleoside phosphorylase in cultured cells. Biochim Acta 928: 130, 1987.
6. Zhang R, Lu Z, Liu T, Soong SJ and Diasio RB: Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res 53: 2816-2822, 1993.
7. Heggic GD, Sommadossi JP, Cross DS, HUSTER WJ and Diasio GD: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206, 1987.
8. Chazal M, Etienne MC, Renee N, Bourgeon A, Tichelme H and Milano G: Link between dihydropyrimidine dehydrogenase activitiy in peripheral blood mononuclear cells and liver. Clin Cacer Res 2: 507-510, 1996.
9. Lu Z, Zhang R, Carpenter J and Diasio RB: Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 4: 325-329, 1998.
10. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Rwnee N, Schneider M, Demard F and Milano G: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12: 2248-2253, 1994.
11. Milano G and Etienne MC: Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. Ther Drug Monit 18: 335-340, 1996.
12. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH, Gesta PH and Larra EG: Relationship between 5-fluorouracil dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77: 441-451, 1996.
13. Sumi S, Kidouchi K, Ohba S and Wada Y: Automated screening system for purine pyrimidine metabolism disorders using high-performance liquid chromatography. J Chromatogr Biomed 672: 233-239, 1995.
14. Ohba S, Kidouchi K, Katoh T, Kobayashi M and Wada Y: Automated determination of orotic acid, uracil and pseudouridine in urine by high-performance liquid chromatography with colum switching. J Chromatogr 568: 325-332, 1995.
15. Kidouchi K, Nakamura C, Katoh T, Ohba S and Wada Y: Automated quantitative analysis for orotidine and uridine/thymidine in urine by high-performance liquid chromatography with colum switching. Adv Exp Med Biol 309B: 31-34, 1991.
16. Matsushima E, Yoshida K, Kitamura R and Yoshida K: Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr Biomed 697: 95-104, 1997.
17. Fety R, Rolland F, Barberi-Heyob M, Merlin JL, Conroy T, Hardouin A, Riviere A and Millano G: Clinical randomized study of 5-FU monitoring versus standard dose in patients with head and neck cancer: preliminary results. Anticancer Res 14: 2347-2352, 1994.
18. Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, Schneider M and Demard F: 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59: 287-290, 1989.
19. Milano G, Roman P, Khater R, Frenay M, Renee N and Namer M: Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer 41: 537-541, 1988.
20. Ogura K, Ohnuma T, Minamide Y, Mizuno A, Nishiyama T, Nagashima S, Kanamaru M, Hiratsuka A, Watabe T and Uematsu T: Dihydropyrimidine dehydrogenase activity in 150 health-Japanese volunteers and identification of novel mutations. Clin Cancer Res 11: 5104-5111, 2005.
21. Fernandez-Salguero P, Gonzalez FJ, Etienne MC, Milano G and Kimura S: Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes. Biochem Pharmacol 50: 1015-1020, 1995.
22. Wei X, McLeod HL, McMurrough J and Gonzalez FJ: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98: 610-615, 1996.
23. van Kuilenburg ABP, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ and van Gennip AH: Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 7: 1149-1153, 2001.
24. Raida M, Schwabe W, Hausler P, Van Kuilenburg AB, Van Gennip AH, Behnke D and Hoffken K: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7: 2832-2839, 2001.
25. Steiner M, Seule M, Steiner B, Bauer I, Freund M, Köhne CH and Schuff-Werner P: 5-fluorouacil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case. J Clin Pathol 58: 553-555, 2005.
26. Schneider HB and Becker H: Dihydropyrimidine dehydrogenase deficiency in a cancer patient undergoing 5-fluorouracil chemotherapy. Anticancer Res 24: 1091-1092, 2004.
27. van Kuilenburg ABP: Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40: 939-950, 2004.
28. Celik L, Kars A, Guc D, Tekuzman G and Ruacan S: Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Cancer Invest 20: 333-339, 2002.
29. Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H and Gonzalez FJ: Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51: 391-400, 1998.
30. Yamaguchi K, Arai Y, Kanda Y and Akagi K: Germline mutation of dihydropyrimidine dehydrogenase gene among a Japanese population in relation to toxicity to 5-Fluorouracil. Jpn J Cancer Res 92: 337-342, 2001.
31. Lu Z, Zhang R and Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53: 5433-5438, 1993.
32. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N and Robert J: Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determinig optimal 5-FU dosage. J Clin Oncology 17: 1105-1110, 1999.
33. Ciccolini J, Mercier C, Blachon MF, Favre R, Durand A and Lacarelle B: A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J Clin Parmacy and Therapeutics 29: 307-315, 2004.
34. Remaud G, Boisdron-Celle M, Hameline C, Morel A and Gamelin E: An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice. J Chromatogr B Analyt Technol Biomed Life Sci 823: 98-107, 2005.
35. Hayashi K, Kidouchi K, Sumi S, Mizokami M, Orito E, Kumada K, Ueda R and Wada Y: Possible prediction of adverse reactions to pyrimidine chemotherapy from urinary pyrimidine levels and a case of asymptomatic adult dihydropyrimidinuria. Clin Cancer Res 2: 1937-1941, 1996.
36. Jiang H, Lu J and Ji J: Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropirimidine dehydrogenases levels. British J Parmacol 141: 616-623, 2004.